Maridebart Cafraglutide Side Effects: What Studies Report

Maridebart cafraglutide has been described in the published literature as an investigational molecule that pairs a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist antibody with glucagon-like peptide-1 (GLP-1) receptor agonist peptides, a design intended to combine GIPR blockade with GLP-1 receptor activation (PMID 38316982). Because the compound is investigational, the available safety picture comes from a small number of clinical reports rather than from post-marketing surveillance. This page summarises what those reports state about adverse events, and where the record is silent it says so plainly. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication or investigational compounds.

Where the Safety Data Come From

Two primary clinical sources dominate the published record. The first is a 2024 Nature Metabolism report in which researchers characterised the conjugate in preclinical models and then described first-in-human phase 1 single-ascending-dose and multiple-ascending-dose experience in people with obesity, reporting weight loss alongside changes in metabolic parameters (PMID 38316982). The second is a 2025 New England Journal of Medicine phase 2 trial in which researchers evaluated once-monthly subcutaneous maridebart cafraglutide for the treatment of obesity across multiple dose groups over 52 weeks, with and without a dose-escalation approach (PMID 40549887).

Broader context comes from review literature on incretin-based pharmacotherapy. A 2026 perspective in Metabolism Open placed multi-receptor agonists and next-generation metabolic modulators within an evolving obesity treatment landscape and discussed tolerability and unresolved controversies across the class (PMID 41948476). A 2026 review in Pharmaceutics examined GLP-1 and GLP-1/GIP receptor agonists in the setting of diabetes mellitus and stroke, describing the pathophysiological rationale and therapeutic potential of incretin receptor–directed agents (PMID 42198313). Those reviews are class-level; they do not substitute for compound-specific adverse-event data.

Gastrointestinal Events: What Studies Report

Across both clinical reports, gastrointestinal complaints were the adverse events researchers described most frequently. In the phase 1 setting, the 2024 report characterised adverse events as predominantly mild-to-moderate gastrointestinal in nature in participants receiving the conjugate (PMID 38316982). In the 52-week phase 2 trial, researchers again reported gastrointestinal adverse events — nausea and vomiting among them — as the most common events and described them as mostly mild to moderate in severity (PMID 40549887).

The pattern is consistent with what review literature describes for incretin receptor–directed therapies generally, where gastrointestinal intolerance is the dominant reason cited for treatment burden and early cessation across the class (PMID 41948476). What the published abstracts for maridebart cafraglutide do not provide is a granular breakdown of every gastrointestinal symptom by dose group and week, so readers should treat any more specific figure circulating outside the peer-reviewed reports as unverified.

Why Monthly Administration Is Discussed in the Tolerability Literature

Maridebart cafraglutide was studied on a once-monthly schedule rather than a weekly one, and the phase 2 trial evaluated this once-monthly subcutaneous administration over 52 weeks (PMID 40549887). The phase 1 work likewise examined repeated dosing at monthly intervals in its multiple-ascending-dose portion (PMID 38316982). Extended-interval dosing raises questions researchers have not fully answered in the published record — for example, how symptom intensity after each administration compares with more frequent regimens of other agents. The trials described tolerability qualitatively rather than resolving that comparison.

Dose Escalation and Tolerability: What the Trials Examined

Dose escalation is a standard tolerability tool in incretin research, and the phase 2 trial included groups that reached target dosing with escalation as well as groups that did not, with researchers reporting outcomes over 52 weeks (PMID 40549887). The presence of escalation and non-escalation arms indicates the study was designed in part to characterise how the approach to reaching a target dose relates to tolerability, and the report of that trial is the appropriate source for anyone examining that question in detail (PMID 40549887). This page does not describe any dose amount, schedule or escalation approach as appropriate for an individual; the trial protocols were research protocols conducted under investigator supervision.

Discontinuation and Severity: What Studies Report

The phase 2 trial reported that some participants receiving maridebart cafraglutide discontinued treatment because of adverse events, alongside the observation that most reported events were mild to moderate (PMID 40549887). Discontinuation for tolerability reasons is a recurring theme in the wider class literature, where reviews have noted that real-world persistence with incretin-based therapy is shaped heavily by side-effect burden as well as by access and cost factors (PMID 41948476).

The phase 1 report similarly framed its findings as demonstrating weight loss with improved metabolic parameters while describing adverse events as mild to moderate in the participants studied (PMID 38316982). Neither published abstract describes the compound as free of adverse effects, and neither establishes a rare-event profile, which would require far larger and longer exposure than the published trials provided (PMID 40549887).

Preclinical Observations: What Studies Report

Before human dosing, researchers evaluated the GIPR antagonist–GLP-1 analogue conjugate in preclinical models and reported weight loss with improvement in metabolic parameters, which formed the rationale for advancing into phase 1 (PMID 38316982). Preclinical toxicology findings are not the same as human adverse events, and animal observations do not predict human symptom frequency; the 2024 report is cited here only for the developmental sequence it describes (PMID 38316982).

Reported Adverse-Event Themes at a Glance

What the Literature Does Not Establish

Stating absence honestly matters as much as summarising presence. As of the verified reports reviewed here, the following were not established in the published maridebart cafraglutide record:

• Long-term safety. The longest published human exposure is the 52-week phase 2 trial, so multi-year adverse-event rates were not characterised (PMID 40549887).
• Rare and serious event rates. Phase 2 sample sizes are not designed to quantify uncommon events; the trial report describes its own findings rather than a definitive risk profile (PMID 40549887).
• Pregnancy, lactation and paediatric data. No such data appear in the phase 1 or phase 2 reports cited here (PMID 38316982).
• Dedicated organ-impairment or drug-interaction studies. The reports reviewed here did not present renal or hepatic impairment substudies or interaction analyses (PMID 40549887).
• Cardiovascular outcome results. Class reviews discussed potential cardiometabolic and cerebrovascular relevance of incretin receptor agents, but that literature is not an outcome trial of this compound (PMID 42198313).
• Body-composition controversies. Reviews of next-generation metabolic modulators flagged questions such as lean-mass change and durability as open debates across the field rather than settled findings (PMID 41948476).

Because maridebart cafraglutide has been studied as an investigational agent in phase 1 and phase 2 trials, its adverse-event profile is provisional by definition (PMID 40549887). Material sold outside a clinical trial or an approved prescription pathway is not the material characterised in these publications, and no published study has evaluated the safety of such material.

How Class Context Should and Should Not Be Used

It is tempting to fill gaps in a single compound's record with data from better-studied incretin drugs. Review literature does describe shared mechanisms: GLP-1 receptor activation and combined incretin receptor targeting have been reviewed for their metabolic and vascular relevance in diabetes and stroke (PMID 42198313), and perspectives on multi-receptor agonists have summarised how tolerability and controversy have travelled with the class (PMID 41948476). But maridebart cafraglutide differs structurally from agonist-only peptides, since researchers described it as a GIPR antagonist antibody conjugated to GLP-1 analogues (PMID 38316982). Receptor-level differences mean class extrapolation is a hypothesis-generating exercise, not evidence about this molecule.

Reading the Primary Reports Directly

Readers who want the numbers behind these summaries — event frequencies by dose group, severity grading, and the study's own tolerability discussion — will find them in the phase 2 publication itself (PMID 40549887) and in the phase 1 and preclinical report (PMID 38316982). PeptideU's separate course on maridebart cafraglutide covers the pharmacology, molecular design and trial-design questions in teaching form; this page is limited to what the literature reported about adverse events and to naming the gaps. Neither page constitutes medical advice, and clinical decisions belong with a licensed physician who can weigh an individual's circumstances.

References

• Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial (The New England Journal of Medicine, 2025)
• A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings (Nature Metabolism, 2024)
• Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies (Metabolism Open, 2026)
• Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists (Pharmaceutics, 2026)